Cart
sales@molnova.com
S-Ruxolitinib
CAS No. 1160597-27-2
S-Ruxolitinib( —— )
Catalog No. M19421 CAS No. 1160597-27-2
Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameS-Ruxolitinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionRuxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.
-
DescriptionRuxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays >130-fold selectivity for JAK1/2 versus JAK3.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK1| JAK2
-
Research AreaCardiovascular Disease
-
IndicationMyelofibrosis; Polycythaemia Vera
Chemical Information
-
CAS Number1160597-27-2
-
Formula Weight306.37
-
Molecular FormulaC17H18N6
-
Purity>98% (HPLC)
-
SolubilityDMSO:61 mg/mL;Water:<1 mg/mL
-
SMILESN#CCC(C1CCCC1)n2cc(cn2)c4ncnc3nccc34
-
Chemical Name3-(4-(7H-Pyrrolo[23-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Quintas-Cardama A et al. Blood 2010 115(15) 3109-3117.
molnova catalog
related products
-
SHR0302
SHR0302 is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2).
-
LY2784544
LY2784544 (Gandotinib) is a potent, selective and ATP-competitive inhibitor of JAK2V617F.
-
Upadacitinib
Upadacitinib (ABT-494) is a potent and selective JAK1 inhibitor with celluar IC50 of 8 nM, biochemical IC50 of 40 nM.
